报告

  WAPN+ facilitated a treatment literacy and advocacy training forum in Bangkok, Thailand, at the end of September 2010. The training was attended by 22 participants from 13 countries in the Asia Pacific region.

  Treatment literacy can be defined as understanding HIV/AIDS and all aspects of antiretroviral therapy (ART), including types of ARV drugs, how they work, ARV side effects, treatment adherence, HIV drug resistance and other issues. Treatment literacy is essential to ensuring that people living with HIV are well informed and in a position to participate more actively in treatment, including communicating treatment needs to health care providers.  It is also important to have the knowledge and capacity to hold governments accountable and to ensure they improve the quality and accessibility of health services and the quality of ARV treatment.

The attached report provides a full account of the 3 day forum.

Organization: APN+

Weblink: http://www.apnplus.org/main/Index.php?module=news&news=64


    2010年9月WAPN+在泰国曼谷开展了治疗教育和倡导的培训。来自亚太地区13个国家的22人参加和培训。

    治疗教育包含HIV/AIDS和抗逆转录病毒治疗(ART)的方方面面,例如ARV药物的类型、药效、副作用、治疗坚持度、HIV抗药性,等等。治疗教育能够保证艾滋病毒携带者的知情权,并帮助他/她们积极地参与治疗,例如与医护人员针对治疗需求进行沟通。同时,艾滋病患也需要监督政府,推动其提高卫生服务以及ARV治疗的质量与可达性。


详细信息请参考为期三天的培训报告:Report WAPN TL Training 30 Sep-2 Oct 2010_New.pdf

机构: APN+ - 亚太艾滋病感染者网络



30TH ANNIVERSAR​Y OF THE FIRST REPORTED CASES OF AIDS


STATEMENT OF ANTHONY S. FAUCI, M.D., AND JACK WHITESCARVER, PH.D.,
NATIONAL INSTITUTES OF HEALTH, ON THE 30TH ANNIVERSARY OF THE FIRST REPORTED CASES OF AIDS

On June 5, 1981, an article concerning five previously healthy, young gay men in Los Angeles diagnosed with Pneumocystis carinii pneumonia, an infection that usually appears only in individuals with substantial immune system damage, appeared in the Morbidity and Mortality Weekly Report, a publication of the Centers for Disease Control and Prevention.
Soon more cases like these appeared, at first mainly in gay men, but then also in injection drug users, hemophiliacs and other recipients of blood and blood products, heterosexual men and women, and babies who acquired the infection from their mothers during birth or breastfeeding. We and our colleagues quickly began to confront the reality of a deadly new disease that would change the world. The disease ultimately would be referred to as AIDS.

Thirty years later, we are gratified by the progress that has been made in understanding, treating and preventing HIV/AIDS. We could not have imagined these advances during the early days of AIDS, when all we could do was provide palliative care to waves of dying patients. Whereas survival was once measured in weeks or months from the time of diagnosis, today, the critical discovery of antiretroviral drugs and their use in combination regimens has resulted in greatly improved life expectancy -- decades, rather than months -- for many HIV-infected people who have access to these medicines and adhere to treatment.

We take pride in the contributions of NIH-supported scientists who have been central to the investigation of the HIV disease process, the development of new therapies for HIV/AIDS and the design and validation of methods of HIV prevention. NIH scientists played a key role in demonstrating that HIV causes AIDS and in developing a diagnostic test for the virus. The ability to test the blood supply for HIV has nearly eliminated the risk of HIV transmission through blood transfusion.

NIH has supported basic and clinical research that provided pivotal data for many of the more than 30 drugs that have been approved by the Food and Drug Administration to treat HIV infection, as well as for strategies to address its associated opportunistic infections, malignancies and clinical complications. Clinical trials funded by NIH also have helped determine the most effective combinations of these drugs to slow or halt the progression of HIV disease. Additionally, NIH-supported studies were instrumental in designing effective strategies to virtually eliminate mother-to-child HIV transmission in developed nations and to dramatically reduce HIV transmission from an infected mother to her newborn or nursing child in the developing world. Many of these clinical trials were designed with the involvement and advice of HIV-affected communities, establishing a model for the conduct of clinical trials for other diseases.

NIH-supported, large-scale clinical trials have resulted in other notable achievements in HIV prevention. These studies sought answers to questions of critical importance to the global public health community. They proved that medically supervised adult male circumcision <http://www.niaid.nih.gov/news/newsreleases/2006/Pages/AMC12_06.aspx> more than halves the risk of female-to-male sexual HIV transmission; that needle and syringe exchange programs can reduce HIV transmission without increasing injection drug use; that a vaccine <http://www.niaid.nih.gov/news/newsreleases/2009/pages/thaivaxstudy.aspx> can achieve modest protection against HIV infection; and that taking an antiretroviral drug daily <http://www.niaid.nih.gov/news/newsreleases/2010/Pages/iPrEx.aspx> can reduce the risk of HIV acquisition in men who have sex with men.

Most recently, an NIH-funded clinical trial <http://www.niaid.nih.gov/news/newsreleases/2011/Pages/HPTN052.aspx> demonstrated that an HIV-infected individual can dramatically reduce the risk of transmitting the virus to an uninfected heterosexual partner by starting treatment when his or her immune system is relatively healthy. NIH also helped train the scientists and establish the infrastructure for an important clinical trial funded by the U.S. Agency for International Development showing that a vaginal gel containing an anti-HIV drug can help protect women from HIV infection. These multiple achievements are important because it is clear that controlling -- and ultimately ending -- the HIV/AIDS pandemic will require a combination of scientifically proven HIV prevention tools.

As gratified as we are by these accomplishments, we are sobered by some grim realities and remaining challenges. Despite the global public health community's best efforts to prevent new infections, 2.6 million people around the world became newly infected with HIV in 2009 alone. In developing nations, only about one-third of the 15 million people who need anti-HIV drugs have access to them. In addition, a growing proportion of patients receiving long-term antiretroviral therapy are experiencing treatment failure, drug toxicities, side effects and drug resistance. In this regard, recent studies have noted an increased incidence of malignancies, cardiovascular and metabolic complications and premature aging associated with long-term HIV disease or antiretroviral therapy.

NIH research will continue to address these issues as well as the causes of HIV-related health disparities, their role in disease transmission and acquisition, and their impact on treatment access and effectiveness. These include disparities among racial and ethnic populations in the United States; disparities between developed and resource-constrained nations, and disparities based on gender, age, or sexual identity. NIH research also will continue to play a critical role in providing the scientific foundation to achieve the goals of the President's National HIV/AIDS Strategy. Among the important scientific challenges that remain are the development of a safe and effective vaccine that can take its place among the combination of prevention tools as well as the possibility of curing at least a proportion of HIV-infected individuals.

The HIV/AIDS pandemic will remain one of the most serious public health crises of our time until better, more effective and affordable prevention and treatment regimens are developed and universally available. As the single largest public funder of HIV/AIDS research in the world, NIH is committed to advancing a comprehensive program of basic, clinical, translational and behavioral and social science research toward controlling and ultimately ending this modern plague. In memory of the patients, friends, loved ones and colleagues we have lost over these three decades, we wholeheartedly embrace this responsibility and opportunity knowing that history will judge us as much for what we accomplish during the coming years as for what we have achieved thus far.

Dr. Anthony S. Fauci is the director of the National Institute of Allergy and Infectious diseases. Dr. Jack Whitescarver is the NIH associate director for AIDS research and the director of the NIH Office of AIDS Research.

NIAID conducts and supports research -- at NIH, throughout the United States, and worldwide -- to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at <http://www.niaid.nih.gov/ >.

The Office of AIDS Research, a part of the Office of the NIH Director, coordinates the scientific, budgetary, legislative, and policy elements of the NIH AIDS research program.   OAR sets scientific priorities, enhances collaboration, and ensures that research dollars are invested in the highest priority areas of scientific opportunity that will lead to new tools in the global fight against AIDS.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
美国国家卫生研究院(NIH)医学博士Anthony S. Fauci、博士Jack Whitescarver为艾滋三十周年发表讲话。

    1981年6月5日,三名来自洛杉矶的年轻男同性恋者被诊断出患有卡氏肺囊虫肺炎,这种疾病通常只有在病患免疫体遭受破坏时才会感染,该病例报告发布于美国疾病控制与防治中心期刊《发病率与死亡率周报》上。

    三十年过去了,我们对在认识、预防与治疗艾滋病方面所取得的进步非常欣喜。NIH所支持的科学家们在艾滋病毒调查、新型治疗方法的研发、以及设计和实验艾滋病预防方法等方面所取得的进步令我们深感骄傲。

    NIH支持的艾滋病预防大型临床实验取得了显著的成果。这些研究解答了很多全球卫生系统共同面临的问题,证明了在严格的医学监控下,对成年男性进行包皮环切手术能够降低一半以上由女性传染的艾滋病毒的风险(http://www.niaid.nih.gov/news/newsreleases/2006/Pages/AMC12_06.aspx );针头和注射器交换项目可以在不增加注射吸毒的基础上降低艾滋病毒的传播; 注射疫苗能在一定程度上防治艾滋感染(http://www.niaid.nih.gov/news/newsreleases/2009/pages/thaivaxstudy.aspx );每日服用抗逆转录药物能够降低男男性行为者感染艾滋的风(http://www.niaid.nih.gov/news/newsreleases/2010/Pages/iPrEx.aspx )。

    最近,NIH支持的临床研究(http://www.niaid.nih.gov/news/newsreleases/2011/Pages/HPTN052.aspx )表明,艾滋病毒感染者如果在自身免疫系统相对较健康的情况下开始治疗,其感染健康的异性性伴侣的可能性将大大降低。另外,NIH也协助美国国际开发署对其资助的临床研究人员进行培训,并提供研究所需的基础设施,该研究结果表明含有抗艾滋药物的阴道凝胶能够防治妇女感染艾滋。
 
    这些研究成果对我们的抗艾工作至关重要,它们证明了如果要控制、以及最终结束艾滋感染需要采用大量科学研究证实的艾滋预防方法。

    虽然我们对目前所取得的研究成果感到欣喜,但是我们也清醒地认识到残酷的现实,我们仍面临巨大的挑战。尽管全球卫生系统都尽全力预防新增感染,2009年全球仍有2600万新增感染者。在发展中国家,1500万感染者中只有三分之一的患者能够获得艾滋治疗药物。另外,越来越多长期接受抗逆转录病毒治疗的患者正面临治疗失败、药物中毒、副作用以及抗药性等问题。因此,在长期艾滋疾病与抗逆转录病毒治疗的过程中,研究显示出越来越多关于恶性肿瘤、心血管与新陈代谢并发症、早衰等问题的案例。

    NIH研究将继续针对这些问题开展科研工作,同时也将对与艾滋病毒有关的健康隐患开展研究。在更好、更有效、更廉价的预防和治疗方案发明以及在全球范围内的推广之前,艾滋流行仍将是全球公共卫生系统面临的最严酷的危机之一。NIH将一如既往地致力于临床以及社会科学研究,为控制以及最终消灭这一现代瘟疫而努力。

    Anthony S. Fauci博士是NIH过敏症与传染病学部主管。Jack Whitescarver博士NIH艾滋研究部副主任以及NIH艾滋研究办主任。

    作为美国卫生与人力资源服务部的组成部门,美国国家卫生研究院(NIH)是美国医疗研究机构,旗下包括27个研究所与研究中心。NIH是美国主要的联邦研究机构,支持并开展大量基础的、临床的以及转化型研究,同时也致力于研究普通和罕见疾病的成因、治疗以及治愈方法。

更多信息请登录NIH官方网站www.nih.gov


SPEAKING OUT ADVOCACY TOOLKIT

| 评论(0)

MSMGF

A Toolkit for MSM-Led HIV and AIDS Advocacy

Speaking Out is an advocacy toolkit created to address the urgent need for men who have sex with men (MSM) everywhere to engage in advocacy locally, nationally, and globally to end the HIV epidemic and promote their human rights. The toolkit equips individuals and organizations with tools and techniques that enable them to become advocates right now, whoever and wherever they happen to be.

Now, more than ever, it is important for our communities to identify our own strengths, weaknesses, and needs, advocating as individuals and collectives for our rights in ways that work for us. MSM communities live and breathe in diverse and complex ways, and we must raise our voices on our own terms, from our respective contexts. That is what this toolkit is all about: ensuring we have the tools we need to become more involved in advocating for our rights, in our homes and schools as well as in governments and international forums.

This toolkit builds on advances made in past toolkits from around the world, with some key differences: (1) it is specifically MSM-focused with exercises and ideas that serve as conduits for the energy and contributions of MSM communities; (2) it is built on the belief that organizations can start where they are, and assumes that the skill sets of individual advocates and organizational maturity of MSM groups are wide-ranging and take time to develop; and (3) it approaches HIV and AIDS from a broad human rights framework, balancing public health and human rights approaches toward addressing MSM community susceptibility to HIV.

We hope you find this toolkit useful!  Please do not hesitate to write to us with any questions or concerns at speakingout@msmgf.org.

 

PDF Download>>

Weblink: http://www.msmgf.org/index.cfm/id/262
MSMGF

    《畅所欲言》是一本针对男男性行为者(MSM)所涉及的倡导工具书,以终结艾滋感染、促进人权发展为目标,帮助该群体有效地开展本土、全国和全球层面的倡导活动。本工具书为倡导者和机构提供实用的工具和技巧,帮助他们能够随时随地立即开展活动。

    比起过去任何时候,当前让社区发现自身的优缺点与需求,并用适合自身的方法开展个人或集体的倡导工作是非常重要的。由于MSM社区内部也非常多样化,因此我们必须从自身的角度和环境出发,用我们自己的方法发出自己的声音。这就是本工具书希望达到的目的:确保我们能够找到适合自己的方法和工具来进行维权倡导工作,无论是在家、学校还是在政府和国际层面。

    这本工具书吸取了全世界已出版的工具书的精华,并在此之上建立了本书的独特性:

(1)本书以MSM为目标群体,为其专门设计相关概念和练习;

(2)我们相信各个MSM组织的发展程度不一,个人所掌握的倡导技能也有所不同,因此本书希望各个群体能够以自身发展的阶段为根据,依次为起点开展工作;

(3)本书在一个宽泛的人权架构下来强调艾滋问题,通过对MSM群体对艾滋的敏感度来平衡对公共卫生与人权问题。

如有任何问题,请发送邮件至:speakingout@msmgf.org.

PDF下载>>

Asia Report 翻译

原文链接: http://www.msmgf.org/index.cfm/id/262


FEMINISM, POWER, AND SEX WORK IN THE ONTEXT OF HIV/AIDS: CONSEQUENCES

FOR WOMEN'S HEALTH

 

AZIZA AHMED*

 

  Globally, women constitute approximately fifty percent of all HIV infections. Women may eventually comprise the majority of people living with HIV/AIDS in the world; this is already true in Sub-Saharan Africa where women constitute sixty percent of the individuals living with HIV. The recognition that women's inequality may be a driver of women's vulner- ability to contracting HIV has led to a series of feminist legal responses in an effort to address HIV.

 

  This Article assesses feminists' conflicting legal, policy, and regulatory proposals to address sex workers' vulnerability to contracting HIV. This Article employs a Governance Feminism ("GF") analysis that allows us to assess feminists as powerful actors in the institutions that govern HIV. This Article focuses on two cases in which particular legal and policy proposals can be traced directly to feminist engagement and disagreement: the drafting of the United Nations Joint Programme on HIV/AIDS Guidance Note on Sex Work and the creation and implementation of the Anti-Prostitution Loyalty Oath.


Download PDF>>


艾滋病背景下的女权主义,权利与性工作:对女性健康的影响

作者:Aziza Ahmed

哈佛大学法律与社会性别期刊

 

全球范围内妇女约占艾滋感染人口的一半。在未来,妇女有可能最终将成为主要艾滋感染人口,这种情况在撒哈拉以南的非地区已成为现实,艾滋感染者中60%为妇女。普遍认为妇女的不平等地位是使妇女面对艾滋感染时异常脆弱,这也导致在抗击艾滋的努力中很多出现了一系列女权主义的法律回应。

  本文分析了不同的女性主义者针对性工作者感染艾滋的脆弱性所提出的相互冲突的法律、政策和管理方面的提案。文章采用Governance Feminism分析法让读者了解女权主义者作为有影响力的行动者,积极参与对艾滋问题的管理。本文关注的两个案例可以清晰地表明女权主义者如何参与不同的法律和政策提案,以及如何表达不一致的意见。这两个案例分别是:《联合国联合项目:艾滋指南与性工作须知》和《打击卖淫效忠誓言》的制定和实施。


PDF下载(英文)>>

   Booklet explains unique health needs and sets forth principles of practice for doctors, nurses and other healthcare providers.

 

  May 17, 2011 - The Global Forum on MSM & HIV (MSMGF) has published a new primer for doctors, nurses and other healthcare providers designed to improve the quality of clinical care available to men who have sex with men (MSM) across a broad range of contexts.  Released on May 17, the International Day against Homophobia, the booklet identifies stigma and discrimination as key barriers preventing MSM from accessing vital health services.

 

  Entitled "Engaging with Men Who Have Sex with Men in the Clinical Setting," the primer was developed in response to the unacceptable quality of care offered to MSM at clinics around the world.  High levels of homophobia among clinic staff have led to negligent care and severe violations of patient rights, such as verbal abuse and confidentiality breeches.  In addition, clinical curricula in many low- and middle-income countries have failed to include content on MSM health, leaving healthcare professionals with no knowledge of MSM health needs or the ways to address them.  

 

  Such substandard care has been a primary factor in the surge of HIV among MSM around the world as well as lower health outcomes overall.  More than half of MSM globally report that it is difficult or impossible to access vital services like HIV testing and treatment, while HIV prevalence rates skyrocket above 20% in countries like Senegal, Jamaica and Thailand.  Studies indicate that MSM also experience higher rates of depression, anxiety, substance abuse and suicide due to high levels of stress and alienation from social services and support.

 

  The primer aims to improve the standard of clinical care for MSM by providing basic knowledge about homosexuality and MSM health needs, as well as offering a set of principles for effective engagement of MSM in a healthcare setting.  The booklet begins by dispelling common myths about homosexuality and exploring the role of service providers in meeting the needs of MSM.  These needs are then examined in greater detail, with a focus on sexual health, mental health, drug use and violence.  The primer concludes with a roadmap for healthcare providers, providing guidance on leading community-level engagement with MSM and enhancing local capacity to meet MSM needs.

 

 "Healthcare providers play a central part in the well-being of MSM around the world," said Dr. George Ayala, Executive Officer of the MSMGF. "We have seen how damaging it can be when they are ill-equipped to handle the needs of MSM.  But with the proper tools at their disposal, they have the potential to be an equally powerful force for good.  This primer represents a first step toward that goal."

 

  The primer is currently available in English and can be found on the MSMGF's website at the following link:

http://www.msmgf.org/files/msmgf//Publications/MSMGF_Healthcare_Primer.pdf

 

  Translations are forthcoming in Russian, French and Spanish.  Any questions can be directed to contact@msmgf.org.


Organization: MSMGF

MSMGF


    全球男男艾滋病论坛近期以改善男男性行为者(MSM)的医护质量为目标,针对医生、护士和其他医护人员设计了最新的工作指南。指南在2011517国际不再恐惧同志日发布,声明污名化和歧视是妨碍MSM群体获得关键医疗服务的主要障碍。

   
"男男性行为者所面临的医疗环境"为标题,该指南针对全球MSM群体所接受的质量低下的医护服务给予回应。由于医护人员对同性恋存在高度的恐惧,导致病 患的权利遭到忽视和践踏,例如言语攻击和个人信息外泄。另外,在很多中低收入国家,医疗课程并没有包含MSM健康的相关内容,因此医疗从业人员无法了解 MSM群体的健康需求,更不用谈如何满足这些需求。

   
由于目前艾滋病在MSM群体中迅速传播的现实,对此类医疗标准的需求更加凸显。全球超过一半的MSM人口表示很难或根本不可能获得艾滋病毒测试和治疗,而 与此同时,泰国、牙买家和塞内加尔的艾滋流行率迅速上升20% 研究显示由于无法获得社会服务与支持,MSM人口承受了极高的压力,导致该群体高频率的抑郁、焦虑、滥用药物和自杀。

   
本指南以提高MSM群体医护标准为目标,为医护人员提供同性恋和MSM健康需求的基本知识,同时也提供一整套行之有效的MSM医疗环境参与准则。针对 MSM健康需求,有以下几个主要分类:性健康、心理健康、药物使用与暴力。本指南为医护人员提供如何参与社区层面的MSM治疗,以及如何提高本土医疗能力 以满足MSM群体的需求。


Asia Report 翻译

指南下载(英文):
http://www.msmgf.org/files/msmgf//Publications/MSMGF_Healthcare_Primer.pdf

机构: MSMGF


 

加入邮件组: yzdc@asiacatalyst.org

asia-catalyst.png